Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.18
0.094.31%
At close: -
$2.12
-0.06-2.75%
After Hours: 4:30 PM EDT
Comments
Loading...
Inhibikase Therapeutics Analyst Ratings and Price Targets | NASDAQ:IKT | Benzinga
Inhibikase Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Inhibikase Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
1calculated from analyst ratings
Analyst Ratings for Inhibikase Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/28/2025 | Buy Now | — | HC Wainwright & Co. | Edward White37% | — | Reiterates | Neutral → Neutral | Get Alert |
| 02/12/2025 | Buy Now | — | HC Wainwright & Co. | Edward White37% | — | Downgrade | Buy → Neutral | Get Alert |
| 11/08/2024 | Buy Now | — | Jefferies | Dennis Ding17% | → $8 | Initiates | → Buy | Get Alert |
| 10/14/2024 | Buy Now | — | HC Wainwright & Co. | Edward White37% | $15 → $5 | Maintains | Buy | Get Alert |
| 08/16/2024 | Buy Now | — | HC Wainwright & Co. | Edward White37% | $23 → $15 | Maintains | Buy | Get Alert |
| 05/21/2024 | Buy Now | — | HC Wainwright & Co. | Edward White37% | $27 → $23 | Maintains | Buy | Get Alert |
| 03/07/2024 | Buy Now | — | HC Wainwright & Co. | Edward White37% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2024 | Buy Now | — | HC Wainwright & Co. | Edward White37% | $27 → $27 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | — | HC Wainwright & Co. | Edward White37% | → $27 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | Buy Now | — | HC Wainwright & Co. | Edward White37% | $5 → $27 | Maintains | Buy | Get Alert |
| 06/22/2023 | Buy Now | — | HC Wainwright & Co. | Edward White37% | → $30 | Reiterates | Buy → Buy | Get Alert |
| 04/18/2023 | Buy Now | — | HC Wainwright & Co. | Edward White37% | → $30 | Initiates | → Buy | Get Alert |
| 11/16/2022 | Buy Now | — | JonesTrading | Soumit Roy36% | — | Downgrade | Buy → Hold | Get Alert |
FAQ
What is the target price for Inhibikase Therapeutics (IKT) stock?
The latest price target for Inhibikase Therapeutics (NASDAQ:IKT) was reported by HC Wainwright & Co. on March 28, 2025. The analyst firm set a price target for $0.00 expecting IKT to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Inhibikase Therapeutics (IKT)?
The latest analyst rating for Inhibikase Therapeutics (NASDAQ:IKT) was provided by HC Wainwright & Co., and Inhibikase Therapeutics reiterated their neutral rating.
When was the last upgrade for Inhibikase Therapeutics (IKT)?
There is no last upgrade for Inhibikase Therapeutics
When was the last downgrade for Inhibikase Therapeutics (IKT)?
The last downgrade for Inhibikase Therapeutics Inc happened on February 12, 2025 when HC Wainwright & Co. changed their price target from N/A to N/A for Inhibikase Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Inhibikase Therapeutics (IKT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inhibikase Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inhibikase Therapeutics was filed on March 28, 2025 so you should expect the next rating to be made available sometime around March 28, 2026.
Is the Analyst Rating Inhibikase Therapeutics (IKT) correct?
While ratings are subjective and will change, the latest Inhibikase Therapeutics (IKT) rating was a reiterated with a price target of $0.00 to $0.00. The current price Inhibikase Therapeutics (IKT) is trading at is $2.12, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.